Medivir AB (MVIRb.F) Release: FDA Grants Priority Review to Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C
5/13/2013 9:50:42 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the U.S. Food
and Drug Administration (FDA) has granted Priority Review to the New Drug
Application (NDA) by Janssen for simeprevir (TMC435), an investigational NS3/4A
protease inhibitor administered as a 150 mg capsule once daily with pegylated
interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in
adult patients with compensated liver disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by